Although the exact molecular mechanism underlying the transactivation of EGFR through Ang II-AT1 receptor binding in lung tumor cells is not completely understood, previous clinical studies evidenced an effect of ACE inhibitors or angiotensin type 1 receptor (ATR1) blockers on lung cancer patients, in combination with chemotherapeutics and EGFR inhibitors [64,65]. Here, EGFR is linked to lung carcinoma.